# XP-8121 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/xp-8121

> The next catalyst for XP-8121, sponsored by Xeris Biopharma Holdings, Inc. (XERS), is its topline data readout, late 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for XP-8121?

The next catalyst for XP-8121, sponsored by Xeris Biopharma Holdings, Inc. (XERS), is its topline data readout, late 2028. Press release filed with the SEC (EX-99): "Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030" [Calendar and source filings](https://sec-api.dev/pdufa/xp-8121)

Source: Press release filed with the SEC (EX-99), accession 0001867096-26-000077, https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/exh992xp-8121event.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/pdufa/xp-8121#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | XP-8121 |
| Codes | XP-8121 |
| Sponsor | Xeris Biopharma Holdings, Inc. (XERS) https://sec-api.dev/companies/xers/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2022: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 1.
- First seen 2025-03-06, last confirmed 2025-03-06.
- SEC Form 10-K (accession 0001867096-25-000039): "In October 2022, we reported positive topline Phase 1 data of XP-8121." https://www.sec.gov/Archives/edgar/data/1867096/000186709625000039/xers-20241231.htm

### 2026: trial start

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-03-02, last confirmed 2026-03-02.
- SEC Form 10-K (accession 0001867096-26-000016): "We plan to initiate a Phase 3 clinical trial of XP-8121 in 2026." https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/xers-20251231.htm

### late 2028: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-09-09, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001867096-26-000077): "Initiation of Phase 3 registrational study on track by year-end; topline results expected in late 2028; U.S. FDA approval and launch anticipated in 2030" https://www.sec.gov/Archives/edgar/data/1867096/000186709626000077/exh992xp-8121event.htm
- Press release filed with the SEC (EX-99) (accession 0001867096-26-000114): "Xeris remains on track to initiate Cornerstone by year-end 2026, with topline data expected in late 2028 and potential approval and launch in 2030." https://www.sec.gov/Archives/edgar/data/1867096/000186709626000114/exh991q32026earningsrelease.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/xp-8121.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "XP-8121 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/xp-8121

```bibtex
@misc{secapidev_pdufa_xp_8121_20261116,
  title        = {XP-8121 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/xp-8121}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_xp_8121_20261116","title":"XP-8121 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/xp-8121","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
